🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccination guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid vaccinations during the global health crisis and has concentrated on possible deaths following Covid immunization in her brief time at the FDA.

Scheduled Changes to Pediatric Immunization Program

Health officials planned to announce radical changes to the childhood vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of alignment with much of the global community with little proof for public health gain. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the office this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting certain pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a country with universal health coverage and a citizenry approximately the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Dr. Høeg has no obvious track record in pharmaceutical research, approval processes or management, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Past directors of CBER would “grasp regulatory frameworks and the science of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

This division has an vast workload at the agency, the former commissioner pointed out.

“Many people just focuses on the innovative therapies, but the generic drug division approves thousands of generic medications. There’s a biosimilars division, OTC medication office and more, and each of these have to be managed,” Dr. Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major management aspect to the position, which oversees in excess of 5,000 personnel. “It’s a massive management job, if you execute it properly,” the former official said.

Response and Contentious Initiatives

In response to questions about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on immunizations, a spokesperson responded that the “questions rely on inaccurate presumptions”.

“Her experience matches the responsibilities of her job,” the official said, noting the time Høeg spent advising the FDA commissioner on “medication safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day therapy clearance system that allegedly concerned her predecessors. “How are these drugs being chosen for this voucher program? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of most medications, except for shots.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, past, some experts said. She published a study using unverified volunteer-provided data to estimate the rate of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current government included changing rules for recently developed shots and halting “unnecessary” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccinations.

“She’s an thorough ideologue who commences with her beliefs and reverse-engineers to fit the science in a extremely misleading, fraudulent fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow skeptics, {like|